Medical News Feed
German Drug Data (Deutsch)
Norwegian Drug Data (Norge)
Netherlands Drug Data (Nederlands)
Swedish Drug Data (Sverige)
Want to submit or suggest content for the epgonline.org YouTube Clinical channel?
Contact us here
epgonline.org is not responsible for content on any 3rd party website
Please register to access disease diagnosis, patient management, physician tools.
By viewing the content of this web page you are both confirming your status as a healthcare professional and agreeing to our terms of use.
| Drug class description : | Haemostatics (polyvalent protease inhibitors). |
| Generic Name : | Generic |
| Drug description : | Injection. |
| Presentation : | Injection, aprotinin 10,000 KIU/ mL. |
| Indications : | Aprotonin is a haemostatic. High doses offer major reductions in perioperative blood loss and the need for donor blood transfusions. It is indicated for the treatment of: patients with life threatening haemorrhage due to hyperplasminaemia; patients considered to be at high risk of major blood loss associated with open heart surgery with extracorporeal circulation; patients in whom blood transfusion is not an option so that optimal blood conservation during open heart surgery is an absolute priority (eg, Jehovah's witnesses). |
| Adult Dosage : | To be given by slow intravenous injection or infusion. Hyperplasminaemia: 500,000 to 1, 000,000 KIU (277.8 - 555.6 Ph. Eur. units) (maximum rate 10mL/ minute) followed by 200,000 KIU minute) followed by 200,000 KIU (111.1 Ph. Eur. units) hourly if necessary, until bleeding stops. Open heart surgery: Refer to Summary of Product Characteristics. |
| Child Dosage : | Hyperplasminaemia: It is recommended that a dose proportional to the adult dose, based on body weight, is calculated. Open heart surgery: Dosage has not been established. |
| Elderly Dosage : | Hyperplasminaemia: The dosage above relates to persons of average body weight. Reductions of these doses should be considered in patients of below average weight. Open heart surgery: Refer to Summary of Product Characteristics. |
| Contra Indications : | Known hypersensitivity to aprotinin. |
| Special Precautions : | Avoid rapid intravenous injection of large doses. Caution in patients treated intermittently or patients treated previously with aprotinin; discontinue treatment if hypersensitivity reactions are observed. Adding aprotinin to heparinised blood prolongs activated clotting time. Pregnancy and lactation. |
| Interactions : | None stated. |
| Adverse Reactions : | Local thrombophlebitis, nausea and vomiting, diarrhoea, muscle pains, blood pressure changes. Allergic reactions such as erythema, urticaria and bronchospasm have occurred occasionally. Also, anaphylaxis, tachycardia, pallor or cyanosis, dyspnoea. Reddening of skin on repeated dosage. |
| Manufacturer : | Ferring |
| Drug Availability : | (POM) |
Only registered users have access to the full EPG Online Knowledge Base including drug search tools, interactive disease Knowledge Centres via the EPG Knowledge Library - with clinical and evidence based physician and research tools, MiMedia (build your own clinical media collection with everything from key opinion leader essays to mode of action videos and other multi-media content), the EPG Survey panel, health news updates and much much more.
Already Registered?
Please log-in now using our member login box.
Not a member?
Don't worry, registration is quick and FREE! We welcome all Healthcare professionals, doctors, nurses and medical students.
Register today to have full access to a wealth of drug data, educational and evidence based interactive guides across all major therapeutic areas, disease management, and clinical tools.
As a practicing Healthcare professional, you can also opt-in to join our market research panel – www.epgsurvey.com – and get paid for sharing your expert clinical opinions!
REGISTER today it only takes a minute! and it's FREE
Having problems?
Use our forgotten password facility or email us at: contact@epgonline.org